Stoke Therapeutics (STOK) Liabilities and Shareholders Equity (2018 - 2026)

Stoke Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $443.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 8.94% year-over-year to $443.3 million; the TTM figure through Mar 2026 stood at $1.6 billion (up 25.55% YoY), while the FY2025 annual figure was $418.4 million, up 54.09% from the prior year.
• Liabilities and Shareholders Equity was $443.3 million for Q1 2026 at Stoke Therapeutics, up from $418.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $443.3 million in Q1 2026 to a low of $205.2 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $308.8 million across 5 years, with a median of $293.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity decreased 27.19% in 2024, then jumped 98.31% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $256.1 million in 2022, then declined by 10.83% to $228.3 million in 2023, then rose by 18.92% to $271.6 million in 2024, then surged by 54.09% to $418.4 million in 2025, then increased by 5.94% to $443.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $443.3 million (Q1 2026), $418.4 million (Q4 2025), and $360.3 million (Q3 2025), per Business Quant data.